Charles River initially unveiled a plan to adopt new alternative methods (NAMs), like computer models and human organoids, in ...

The U.S. government has pulled the rug out from under Pluri Biotech’s PLX-R18 cell therapy. | The U.S. government has pulled ...

VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up ...

Alis Biosciences has made a pitch to the hundreds of biotechs that are valued at less than the cash they have in the bank.

After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and ...

Precision Neuroscience has obtained an FDA clearance for a crucial piece of its plans for a full brain-computer interface ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

Biotechs will need to be strategic to achieve “tariff-era success” as the sector enters an “America-first resurgence,” according to a new report from PitchBook. | Biotechs will need to be strategic to ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

Just a few weeks after closing a $155 million series B, RNA editing biotech AIRNA is bringing an experienced gene therapy ...